Volume 77, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


We studied effects of compliance on the impact of mass drug administration (MDA) with diethylcarbamazine and albendazole for lymphatic filariasis (LF) in an Egyptian village. Baseline microfilaremia (mf) and filarial antigenemia rates were 11.5% and 19.0%, respectively. The MDA compliance rates were excellent (> 85%). However, individual compliance was highly variable; 7.4% of those surveyed after five rounds of MDA denied having ever taken the medications and 52.4% reported that they had taken all five doses. The mf and antigenemia rates were 0.2% and 2.7% in those who reported five doses of MDA and 8.3% and 13.8% in those who reported zero doses. There was no significant difference in residual infection rates among those who had taken two or more doses. These results underscore the importance of compliance for LF elimination programs based on MDA and suggest that two ingested doses of MDA are as effective as five doses for reducing filariasis infection rates.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Ottesen EA, 2006. Lymphatic filariasis: treatment, control, and elimination. Adv Parasitol 61 : 395–441. [Google Scholar]
  2. World Health Organization, 2006. Global Programme to Elimination Lymphatic Filariasis. Wkly Epidemiol Rec 81 : 221–232. [Google Scholar]
  3. Michael E, Malecela-Lazaro MN, Kabali C, Snow LC, Kazura JW, 2006. Mathematical models and lymphatic filariasis control: endpoints and optimal interventions. Trends Parasitol 22 : 226–233. [Google Scholar]
  4. Stolk WA, de Vlas SJ, Habbema JD, 2006. Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J 5 : 5. [Google Scholar]
  5. World Health Organization, 2000. Preparing and Implementing a National Plan to Eliminate Lymphatic Filariasis (in Countries where Onchocerciasis is not Co-endemic). Geneva: World Health Organization.
  6. World Health Organization, 2005. Monitoring and Epidemiological Assessment of the Programme to Eliminate Lymphatic Filariasis at Implementation Level. Geneva: World Health Organization. Report No. WHO/CDS/CPE/CEE/2005.50.
  7. Gunawardena S, Ismail M, Bradley M, Karunaweera N, 2007. Factors influencing drug compliance in the mass drug administration programme against filariasis in the Western province of Sri Lanka. Trans R Soc Trop Med Hyg 101 : 445–453. [Google Scholar]
  8. Mathieu E, Direny AN, de Rochars MB, Streit TG, Addiss DG, Lammie PJ, 2006. Participation in three consecutive mass drug administrations in Leogane, Haiti. Trop Med Int Health 11 : 862–868. [Google Scholar]
  9. Vanamail P, Ramaiah KD, Subramanian S, Pani SP, Yuvaraj J, Das PK, 2005. Pattern of community compliance with spaced, single-dose, mass administrations of diethylcarbamazine or ivermectin, for the elimination of lymphatic filariasis from rural areas of southern India. Ann Trop Med Parasitol 99 : 237–242. [Google Scholar]
  10. Babu BV, Kar SK, 2004. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med Int Health 9 : 702–709. [Google Scholar]
  11. Das PK, Ramaiah KD, Vanamail P, Pani SP, Yuvaraj J, Balarajan K, Bundy DA, 2001. Placebo-controlled community trial of four cycles of single-dose diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India. Trans R Soc Trop Med Hyg 95 : 336–341. [Google Scholar]
  12. Rajendran R, Sunish IP, Mani TR, Munirathinam A, Arunachalam N, Satyanarayana K, Dash AP, 2006. Community-based study to assess the efficacy of DEC plus ALB against DEC alone on bancroftian filarial infection in endemic areas in Tamil Nadu, south India. Trop Med Int Health 11 : 851–861. [Google Scholar]
  13. Das PK, Ramaiah KD, Augustin DJ, Kuman A, 2001. Towards elimination of lymphatic filariasis in India. Trends Parasitol 17 : 457–460. [Google Scholar]
  14. Southgate B, 1979. Bancroftian filariasis in Egypt. Trop Dis Bull 76 : 1045–1068. [Google Scholar]
  15. Harb M, Faris R, Gad AM, Hafez ON, Ramzy RM, Buck AA, 1993. The resurgence of lymphatic filariasis in the Nile delta. Bull World Health Organ 71 : 49–54. [Google Scholar]
  16. World Health Organization, 2003. The Global Elimination of Lymphatic Filariasis - The Story of Egypt. Geneva: World Health Organization.
  17. World Health Organization, 2004. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 79 : 358–365. [Google Scholar]
  18. World Health Organization, 2005. Global programme to eliminate lymphatic filariasis. Wkly Epidemiol Rec 80 : 202–212. [Google Scholar]
  19. Ramzy RM, El-Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ, 2006. Effect of yearly mass drug administration with diethycarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367 : 992–999. [Google Scholar]
  20. Weil GJ, Lammie PJ, Weiss N, 1997. The ICT filariasis test: a rapid-format antigen test for diagnosis of bancroftian filariasis. Parasitol Today 13 : 401–404. [Google Scholar]
  21. Weil GJ, Ramzy RM, 2007. Diagnostic tools for filariasis elimination programmes. Trends Parasitol 23 : 78–82. [Google Scholar]
  22. El-Setouhy M, Ramzy RM, Ahmed ES, Kandil AM, Hussain O, Farid HA, Helmy H, Weil GJ, 2004. A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am J Trop Med Hyg 70 : 191–196. [Google Scholar]
  23. Ramzy R, Helmy H, El-Lethy A, Kandil A, Ahmed E, Weil G, Faris R, 2000. Evaluation of a rapid-format kit for diagnosis of bancroftian filariasis in Egypt. Eastern Med Health J 5 : 880–887. [Google Scholar]
  24. Dean AG, Dean JA, Coulombier D, Burton AH, Brendel KA, Smith DC, Dicker RC, Sullivan KM, Fagan RF, 1994. Epi Info, Version 6: A Word Processing, Database, and Statistics Program for Epidemiology on Microcomputers. Atlanta, GA: Centers for Disease Control and Prevention.
  25. El-Setouhy M, Rio F, 2003. Stigma reduction and improved knowledge and attitudes towards filariasis using a comic book for children. J Egypt Soc Parasitol 33 : 55–65. [Google Scholar]
  26. Gyapong M, Gyapong JO, Owusu-Banahene G, 2001. Community-directed treatment: the way forward to eliminating lymphatic filariasis as a public-health problem in Ghana. Ann Trop Med Parasitol 95 : 77–86. [Google Scholar]
  27. Ramaiah KD, Vijay Kumar KN, Chandrakala AV, Augustin DJ, Appavoo NC, Das PK, 2001. Effectiveness of community and health services-organized drug delivery strategies for elimination of lymphatic filariasis in rural areas of Tamil Nadu, India. Trop Med Int Health 6 : 1062–1069. [Google Scholar]
  28. Wamae N, Njenga SM, Kisingu WM, Muthigani PW, Kiiru K, 2006. Community-directed treatment of lymphatic filariasis in Kenya and its role in the national programmes for elimination of lymphatic filariasis. Afr J Health Sci 13 : 69–79. [Google Scholar]
  29. Ismail MM, Jayakody RL, Weil GJ, Fernando D, de Silva MS, de Silva GA, Balasooriya WK, 2001. Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 95 : 332–335. [Google Scholar]
  30. Helmy H, Weil GJ, Ellethy AS, Ahmed ES, El-Setouhy M, Ramzy RM, 2006. Bancroftian filariasis: effect of repeated treatment with diethycarbamazine and albendazole on microfilaremia, antigenemia, and antifilarial antibodies. Trans R Soc Trop Med Hyg 100 : 656–662. [Google Scholar]

Data & Media loading...

  • Received : 18 Jun 2007
  • Accepted : 18 Sep 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error